HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Pediatrics · ECMO Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Pediatrics · ECMO Therapeutic Area Assessment

12 signals · 5 insights · 42 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 65%

Evidence

59 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Pediatrics · ECMO integrates 12 signals, 5 executive insights, and 42 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJun 29, 2026

    GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk

    GE HealthCare has issued a correction for Giraffe and Panda infant resuscitation systems due to a potential loosening of the air-oxygen blender knob shaft, which may affect oxygen delivery.

    View detail
  2. signalJul 15, 2026

    CPAP Trial Aims to Reduce Bronchopulmonary Dysplasia in Premature Infants

    The CPAP Trial is evaluating the impact of prolonged CPAP use on reducing bronchopulmonary dysplasia or death in preterm infants.

    View detail
  3. signalJul 15, 2026

    Machine Learning Study Aims to Diagnose Cholestasis in Newborns Using Parent-Provided Images

    An observational study is evaluating a machine-learning algorithm's ability to diagnose cholestasis and biliary atresia in newborns using stool images provided by parents.

    View detail
  4. signalJul 12, 2026

    FDA Approval Update for Children's Advil (Ibuprofen) by Haleon

    The FDA has accepted a supplemental application for Children's Advil (Ibuprofen) from Haleon.

    View detail
  5. regulatoryJul 15, 2026

    Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)

    As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.

    View detail
  6. regulatoryJul 15, 2026

    Phase 1 IND Learning Resources

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pediatric liver disease treatments.

    View detail
  7. regulatoryJul 12, 2026

    Withdrawn | Cancer Accelerated Approvals

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    View detail
  8. regulatoryJul 12, 2026

    FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)

    Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.

    View detail
  9. insightJul 12, 2026

    Haleon's Children's Advil Approval Enhances Pediatric Market Position

    The FDA's acceptance of a supplemental application for Children's Advil by Haleon is significant as it may strengthen their competitive position in the pediatric analgesic market. This development necessitates close monitoring of Haleon's marketing strategies and the approval timeline to assess potential impacts on market dynamics. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (12 high-relevance).

    View detail
  10. insightJul 2, 2026

    Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    The FDA's approval of Children's Advil-Flavored by Haleon is significant as it enhances their portfolio in pediatric pain management, a critical therapeutic area. This move could shift market dynamics, prompting competitors to reassess their strategies in the OTC space. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (5 high-relevance).

    View detail
  11. insightJun 30, 2026

    Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    The ongoing study on prone positioning in infants with bronchiolitis could lead to significant changes in clinical practice, particularly in pediatric intensive care. If successful, it may alter the standard of care and impact the usage of existing ventilation strategies, necessitating close monitoring by pharma strategy teams. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

    View detail
  12. insightJun 30, 2026

    Regulatory and Competitive Risks for GE HealthCare's Infant Resuscitation Systems

    The correction issued by GE HealthCare for its infant resuscitation systems poses significant safety concerns that could impact patient outcomes and regulatory compliance. This situation necessitates a thorough investigation to understand the implications for product safety and market positioning. Regulatory context from MHRA (Regulation of AI in Healthcare) supports the near-term read. Assessment grounded in 19 ranked evidence items (3 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 5 risk-calibrated assessments for portfolio review. 42 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)

    83%

    As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.

    Source: FDA

    View evidence

  • Phase 1 IND Learning Resources

    83%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pediatric liver disease treatments.

    Source: FDA

    View evidence

  • Withdrawn | Cancer Accelerated Approvals

    95%

    This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

    Source: FDA

    View evidence

  • FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)

    66%

    Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.

    Source: FDA

    View evidence

  • FDA AP — CHILDREN'S ADVIL (SUPPL)

    66%

    Application NDA020944. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.

    Source: FDA

    View evidence

  • FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)

    66%

    Application NDA020589. Sponsor: HALEON US HOLDINGS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: IBUPROFEN.

    Source: FDA

    View evidence

  • Haleon's Children's Advil Approval Enhances Pediatric Market Position

    74%

    The FDA's acceptance of a supplemental application for Children's Advil by Haleon is significant as it may strengthen their competitive position in the pediatric analgesic market. This development necessitates close monitoring of Haleon's marketing strategies and the approval timeline to assess potential impacts on market dynamics. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (12 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    60%

    The FDA's approval of Children's Advil-Flavored by Haleon is significant as it enhances their portfolio in pediatric pain management, a critical therapeutic area. This move could shift market dynamics, prompting competitors to reassess their strategies in the OTC space. Regulatory context from FDA (FDA AP — CHILDREN'S ADVIL-FLAVORED (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    52%

    The ongoing study on prone positioning in infants with bronchiolitis could lead to significant changes in clinical practice, particularly in pediatric intensive care. If successful, it may alter the standard of care and impact the usage of existing ventilation strategies, necessitating close monitoring by pharma strategy teams. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 24 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Regulatory and Competitive Risks for GE HealthCare's Infant Resuscitation Systems

    50%

    The correction issued by GE HealthCare for its infant resuscitation systems poses significant safety concerns that could impact patient outcomes and regulatory compliance. This situation necessitates a thorough investigation to understand the implications for product safety and market positioning. Regulatory context from MHRA (Regulation of AI in Healthcare) supports the near-term read. Assessment grounded in 19 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Digital Health Interventions for Malnutrition in HIV-Exposed Children: Strategic Implications

    88%

    This trial represents a significant step in leveraging digital health interventions to address malnutrition among vulnerable populations. Its outcomes could reshape investment strategies in pediatric care and digital health solutions, particularly in low-resource settings. Regulatory context from FDA (FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)) supports the near-term read. Assessment grounded in 12 ranked evidence items (11 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk

    Safety Signal

  • CPAP Trial Aims to Reduce Bronchopulmonary Dysplasia in Premature Infants

    Trial Update

  • Machine Learning Study Aims to Diagnose Cholestasis in Newborns Using Parent-Provided Images

    Trial Update

  • FDA Approval Update for Children's Advil (Ibuprofen) by Haleon

    Regulatory Approval

  • FDA Approval for Children's Advil-Flavored Supplement by Haleon

    Regulatory Approval

  • Study on Integrating Behavioral Therapy in Primary Care for ADHD in Underserved Children

    Trial Update

  • Study Compares Tracheoscopy Techniques in Neonates With Tracheoesophageal Fistula

    Trial Update

  • Study on ABI Detection in Pediatric ECMO Patients Using Ultrawide MRI

    Trial Update

Insights

  • Haleon's Children's Advil Approval Enhances Pediatric Market Position

    Pediatrics · Analgesic

  • Haleon's FDA Approval of Children's Advil-Flavored Supplement Enhances Pediatric Market Position

    Pediatrics · Pain Management

  • Potential Shift in Pediatric Respiratory Care Practices from Prone Positioning Study

    Pediatrics · Respiratory Disease

  • Regulatory and Competitive Risks for GE HealthCare's Infant Resuscitation Systems

    Pediatrics · Medical Devices

  • Digital Health Interventions for Malnutrition in HIV-Exposed Children: Strategic Implications

    Pediatrics · Malnutrition

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.